---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-074314"
form_type: "8-K"
ticker: "CYRX"
cik: "0001124524"
company_name: "Cryoport, Inc."
filed_at: "2025-08-06T23:59:59+00:00"
generated_at: "2026-05-17T18:53:58.224605+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Cryoport Q2 revenue up 14% to $45.5M; cell & gene therapy revenue +33%; reaffirms FY25 guidance

## Summary
- Net income of $105.2M includes $117.4M gain from CRYOPDP divestiture; adjusted EBITDA improved to -$0.9M vs -$5.6M a year ago.
- Life Sciences Services revenue grew 21% to $24.4M (54% of total); BioStorage/BioServices up 28%.
- Commercial cell & gene therapy revenue rose 33% to $8.7M; supported 18 commercial therapies and 728 global trials.
- Closed strategic partnership with DHL and divestiture of CRYOPDP on June 11, 2025; cash & investments $426M.
- Reaffirmed FY2025 revenue guidance of $165M–$172M, representing 5%-10% YoY growth.

## SEC filing metadata
- accession: 0001104659-25-074314
- form_type: 8-K
- ticker: CYRX
- cik: 0001124524
- company_name: Cryoport, Inc.
- filed_at: 2025-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1124524/000110465925074314/0001104659-25-074314-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1124524/000110465925074314/tm2522626d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-074314
- JSON: https://secwatch.observer/filing/0001104659-25-074314.json
- Plain text: https://secwatch.observer/filing/0001104659-25-074314.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.